ANAKINRA FOR THE TREATMENT OF POST ACUTE COVID SYNDROME

The present invention relates to the human Interleukin 1 Receptor antagonist anakinra for use in the treatment of Post-Acute COVID Syndrome (PACS), wherein said treatment comprises administration of a dose of at least approximately 100 mg of anakinra to a patient in need thereof. Also, related treat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	DOLFI, Fabrizio, GIAMARELLOS-BOURBOULIS, Evangelos, K.-LAFLAMME, Annik
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to the human Interleukin 1 Receptor antagonist anakinra for use in the treatment of Post-Acute COVID Syndrome (PACS), wherein said treatment comprises administration of a dose of at least approximately 100 mg of anakinra to a patient in need thereof. Also, related treatment methods and pharmaceutical compositions for said use are disclosed. La présente invention concerne l'anakinra antagoniste du récepteur de l'interleukine 1 humaine destiné à être utilisé dans le traitement du syndrome de COVID post-aigu (PACS), ledit traitement comprenant l'administration d'une dose d'au moins approximativement 100 mg d'anakinra à un patient en ayant besoin. L'invention concerne également des méthodes de traitement associées et des compositions pharmaceutiques associées pour ladite utilisation.